Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 81.2%

Neg 81.2% Neu 0% Pos 0%

Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $8 to $7.